当前位置: X-MOL 学术Artif. Cells Nanomed. Biotechnol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A systematic review and meta-analysis of long noncoding RNA linc-UBC1 expression and prognosis and clinicopathological phenotypes in human cancers.
Artificial Cells, Nanomedicine, and Biotechnology ( IF 5.8 ) Pub Date : 2020-05-29 , DOI: 10.1080/21691401.2020.1770776
Xiewu Zhang 1 , Haibiao Xie 2 , Manjun Luo 3 , Daqiang Liang 4 , Weihua Lao 1 , Weijun Ma 1 , Yankun Lin 1
Affiliation  

According to previous studies, linc-UBC1 is abnormally expressed in various human tumours. Nonetheless, the clinical significance and mechanism of linc-UBC1 in cancer remains unclear. In our present analysis, we wanted to explore the specific role of linc-UBC1 in malignant tumours by integrating all of the relevant literature and subsequently elucidating the relationship between linc-UBC1 expression level and clinical characteristics of cancers. An elaborate database search of PubMed, Embase, Wanfang Data, Web of Science, Ovid, Medline, Cochrane Library and PMC was carried out up to 8 August 2019. We further applied the pooled odds ratio (OR) and hazard ratio (HR) to evaluate OS. After filtering by strict criteria, 11 studies containing 1017 cases were included in this analysis. Our results implied that high expression of linc-UBC1 was obviously related to poor OS in cancer (HR =1.735, 95% 1.348-2.235, p < .001 random effects model). Analogously, the data revealed that high expression of linc-UBC1 was highly correlated with lymph node metastasis (OR = 2.912, 95% CI: 2.056-4.125, p < .001 fix effects model) and high tumour stage (OR = 2.678, 95% CI: 1.859-3.857, p < .001 fix effects model). In summary, linc-UBC1 overexpression is associated with poor OS and advanced tumour stage and could be used as a novel prognostic biomarker in various cancers.

中文翻译:

长期的非编码RNA linc-UBC1的表达,对人类癌症的预后以及临床病理表型的系统评价和荟萃分析。

根据先前的研究,incl-UBC1在各种人类肿瘤中异常表达。但是,尚不清楚linc-UBC1在癌症中的临床意义和机制。在我们目前的分析中,我们希望通过整合所有相关文献并随后阐明linc-UBC1表达水平与癌症临床特征之间的关系,来探索linc-UBC1在恶性肿瘤中的特定作用。截至2019年8月8日,我们对PubMed,Embase,Wanfang Data,Web of Science,Ovid,Medline,Cochrane图书馆和PMC进行了详细的数据库搜索。我们进一步将合并的优势比(OR)和危险比(HR)应用于评估操作系统。按照严格的标准过滤后,该分析包括11项研究,涉及1017例病例。我们的结果表明,linc-UBC1的高表达显然与癌症的OS差有关(HR = 1.735,95%1.348-2.235,p <.001随机效应模型)。类似地,数据显示linc-UBC1的高表达与淋巴结转移(OR = 2.912,95%CI:2.056-4.125,p <.001固定效应模型)和高肿瘤分期(OR = 2.678,95)高度相关。 %CI:1.859-3.857,p <.001固定效果模型)。总之,lnc-UBC1过表达与较差的OS和晚期肿瘤分期有关,可以用作各种癌症的新型预后生物标志物。001固定效应模型)和高肿瘤分期(OR = 2.678,95%CI:1.859-3.857,p <.001固定效应模型)。总之,lnc-UBC1过表达与较差的OS和晚期肿瘤分期有关,可以用作各种癌症的新型预后生物标志物。001固定效应模型)和高肿瘤分期(OR = 2.678,95%CI:1.859-3.857,p <.001固定效应模型)。总之,lnc-UBC1过表达与较差的OS和晚期肿瘤分期有关,可以用作各种癌症的新型预后生物标志物。
更新日期:2020-05-29
down
wechat
bug